This observation is consistent with previous findings linking CDK4 amplification to aggressive tumor phenotypes and CNS involvement.[8] Moreover, given the limited therapeutic options for SCLC, CDK4 inhibitors may offer a promising targeted approach for patients with such alterations. Here, CDK4 is linked to neoplasm.